Epizyme


3 “Strong Buy” Biotech Stocks with FDA Approvals on the Horizon

COVID-19 has turned the world upside down, but the market’s most recent surge has Wall Street observers wondering if the situation is on the mend. Rallying on April 17 thanks to encouraging data from Gilead’s remdesivir COVID-19 drug …

H.C. Wainwright Reaffirms Buy On Epizyme On The Heels Of Disappointing DOT1L Expansion Data

In a research note published today, H.C.

Wedbush Reiterates Buy On Epizyme Following 2Q14 Update And Positive Early-Stage EPZ-6438 Data

In a research report released today, Wedbush analyst David Nierengarten reiterated an Outperform rating on Epizyme (NASDAQ:EPZM) with a $52 price target, following the company’s second-quarter financial results and update on …

H.C. Wainwright Initiates Buy On Epizyme; Sees 30% Upside For Stock

In a research note released this morning, H.C.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts